

REMARKS

The Amendment, filed in response to the Office Action mailed December 30, 2009, is believed to fully address all and every issue raised in the Office Action. Favorable reconsideration of the merits and allowance of the application are respectfully requested.

Disposition of Claims

In the Office Action, Claims 1-5, 9-11, 33, and 34 have been considered and rejected. Claims 7, 8, and 12-32 have been withdrawn as being directed to non-elected subject matter.

In the instant Amendment, claims 1-5, 9-11, and 33 are amended for the interests of Applicant to advance the prosecution. Claim 34 is canceled without prejudice or disclaimer.

No new matter is introduced. Entry and consideration of the amendments are respectfully requested.

Response to Claim Objection

In the Office Action, claims 9 and 10 are objected to because they contain misspelled word "folksolin." In response, the word "folksolin" is corrected to read "forskolin."

Therefore, withdrawal of the objection is respectfully requested.

Response to Claim Rejections (Written Description Rejection)

In the Office Action, claims 2-4 and 9 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. In particular, the Examiner asserts that previous amendments made to these claims change the scope of the amounts of glucose, pyruvate, SCF and EGF.

In response, without conceding the rejection, solely in order to advance the prosecution, claims 2, 3 and 9 are amended by the way of canceling the recitation of the ranges of the amounts of D-glucose, sodium pyruvate, SCF and EGF.

Accordingly, withdrawal of the rejection is respectfully requested.

Response to Claim Rejection (Enablement Rejection and Indefiniteness Rejection)

In the Office Action, claims 1-5, 9-11, 33, and 34 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. In particular, the subject matter containing a “stem cell” defined in the claims is rejected as assertedly lacking an enabling disclosure.

Also, the Examiner points out that the term "endothelial growth factor (EGF)" lacks an art-recognized definition, because the acronym "EGF" is accepted in the art as an abbreviation for epidermal growth factor, while there is no molecule accepted by the art as having the name "endothelial growth factor."

In the Office Action, Claims 1-5, 9-11, 33, and 34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, with respect to the terms “stem cell” and “endothelial growth factor (EGF).”

In the Office Action, Claim 34 is rejected as assertedly being confusing in that it is drawn to a composition, but its recitation "which is administered into a subject in need thereof" is a process limitation.

In response, the term "stem cell" is canceled from the claims under consideration.

The term "endothelial growth factor (EGF)" is corrected to read "epidermal growth factor (EGF)." Also, Applicant thanks the Examiner for allowing Applicant to correct the typographical error.

And, claim 34 is canceled without prejudice or disclaimer.

Accordingly, it is believed that the rejections and concerns discussed in the Office Action are rendered moot by amendments made to the claims. Withdrawal of the rejections and allowance of the application are respectfully requested.

Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number **202-775-7588**.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Sunhee Lee/

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Sunhee Lee
Registration No. 53,892

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 30, 2010